Drug Profile
Follitropin alfa biosimilar - Zydus Lifesciences
Alternative Names: r-hFSHLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Female infertility
Most Recent Events
- 21 Oct 2020 Registered for Female infertility in India (SC) (Zydus Cadila pipeline, October 2020)
- 01 Oct 2020 Preregistration for Female infertility in India (SC), before October 2020 (Zydus Cadila pipeline, October 2020)
- 03 Jan 2018 Cadila Healthcare completes a phase III trial in Female infertility in India, before January 2018 (SC) (CTRI2016-10-007367)